Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-09-27
2005-09-27
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S234000
Reexamination Certificate
active
06949549
ABSTRACT:
A class of substituted imidazolo[5,1-a]phthalazine derivatives as ligands for GABAAreceptors of formula Iwhich are partial or full inverse agonists of an α5 receptor subunit while being relatively free of activity at α1 and/or α2 and/or α3 receptor subunit binding sites are described herein; they are therefore of benefit as a medicament for enhancing cognition but with the reduction or elimination of proconvulsant activity.
REFERENCES:
patent: 6528649 (2003-03-01), Cai et al.
patent: WO 94 22865 (1994-10-01), None
patent: WO 98 04559 (1998-02-01), None
patent: WO 98 37648 (1999-07-01), None
Maubach, Medline Abstract for Current Drug Targets-CNS & Neurological Disorders, vol. 2,p. 233-239 (2003).
X. Zhao, R. Zhang: Synth. Commun., vol. 25, 20, 1995, pp. 3271-3286, XP001033825.
Jelley Richard Alexander
Ladduwahetty Tamara
MacLeod Angus Murray
Madin Andrew
Sternfeld Francine
Bernhardt Emily
Merck Sharp & Dohme Ltd.
Todaro John C.
Winokur Melvin
LandOfFree
Imidazolophthalazine derivatives as ligands for GABAA receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazolophthalazine derivatives as ligands for GABAA receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolophthalazine derivatives as ligands for GABAA receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3380995